Age-related Macular Degeneration (AMD) Drugs Market Growth and Restrain Factors Analysis Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2031"

The Global Age-related Macular Degeneration (AMD) Drugs Market is valued at US$ 9.58 Bn in 2023, and it is expected to reach US$ 19.77 Bn by 2031, with a CAGR of 9.7% during the forecast period of 2024-2031.

Request For Free Sample Pages:

https://www.insightaceanalytic.com/request-sample/2854

Age-Related Macular Degeneration (AMD) is a progressive ocular disease primarily affecting the elderly population, leading to degeneration of the macula, the region of the retina responsible for sharp central vision.

The AMD drug market is primarily driven by anti-VEGF therapies, such as Eylea and Lucentis, which are widely used for the treatment of wet AMD. However, recent advancements have introduced innovative therapies for dry AMD, a segment that previously lacked effective treatment options. Emerging drugs such as Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) provide new hope for patients affected by geographic atrophy and macular degeneration, significantly expanding treatment possibilities.

The introduction of new and effective therapies enhances the quality of life for individuals affected by AMD, reinforcing the market’s expansion and ensuring patients have access to treatments that help preserve vision and slow disease progression.

List of Prominent Players in the Age-related Macular Degeneration (AMD) Drugs Market:

·      Regeneron Pharmaceuticals Inc. (US)

·      Bayer AG (Germany)

·      F. Hoffmann-La Roche AG (Switzerland)

·      Novartis AG (Switzerland)

·      Apellis Pharmaceuticals, Inc. (US)

·      Coherus BioSciences, Inc. (US)

·      Astellas Pharma Inc. (Japan)

·      Biogen (US)

·      STADA Arzneimittel AG (Germany)

·      Formycon AG (Germany)

·      Biocon. (India)

·      Outlook Therapeutics, Inc. (US)

·      Intas Pharmaceuticals Ltd. (India)

·      Teva Pharmaceutical Industries Ltd. (Israel)

·      Chengdu Kanghong Biotech Company (China)

·      Sandoz Group AG (Switzerland)

·      Stealth BioTherapeutics Inc. (US)

·      Ocular Therapeutix, Inc. (US)

·      Opthea Limited, Inc. (Australia)

·      Kodiak Sciences Inc. (US)

Market Dynamics:

Drivers-

The Age-Related Macular Degeneration (AMD) drug market is experiencing significant growth, driven by multiple factors. The increasing global prevalence of AMD, particularly among the aging population, is a key contributor to market expansion. Lifestyle-related risk factors, including poor dietary habits, smoking, and sedentary behavior, further accelerate the incidence of AMD.

Advancements in drug development have led to the approval of innovative therapies, such as Pegcetacoplan (Syfovre) and Avacincaptad Pegol (Izervay), specifically for dry AMD, while long-acting anti-VEGF treatments have improved wet AMD management. These innovations enhance treatment efficacy and patient outcomes.

Curious about this latest version of the report? @

https://www.insightaceanalytic.com/enquiry-before-buying/2854

Challenges:

Despite advancements, several challenges may hinder market growth. The high cost of AMD treatments, particularly anti-VEGF therapies such as Eylea and Vabysmo, poses a significant barrier to accessibility. The availability of off-label alternatives often leads to non-adherence, impacting market growth.

Furthermore, dry AMD has historically been under-treated, with many patients relying on dietary supplements rather than pharmacological interventions. This limited scope of treatment options has slowed market expansion in this segment.

Regional Trends:

North America holds a leading position in the AMD drug market, driven by strong pharmaceutical R&D capabilities and the presence of major pharmaceutical companies and research institutions dedicated to developing novel therapies. Substantial investment in research and clinical trials has led to the rapid approval of new treatments, such as Enzeevu, a biosimilar for wet AMD.

The region’s advanced healthcare infrastructure enables early diagnosis and effective treatment interventions, further contributing to market growth. Additionally, regulatory support, particularly from the U.S. Food and Drug Administration (FDA), has accelerated the approval process for emerging therapies.

Recent Developments:

·      In August 2023, Regeneron Pharmaceuticals announced that the U.S. FDA has approved EYLEA HD (aflibercept) 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

·      In March 2022, Novartis announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second EC-approved indication following wet age-related macular degeneration in 2020.

For More Customization @

https://www.insightaceanalytic.com/customisation/2854

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market-

By Products:

·      Lucentis

·      Eylea & Eylea HD

·      Vabysmo

·      Syfovre

·      Other Products

By Molecules:

·      Ranibizumab

·      Aflibercept

·      Faricimab

·      Pegcetoplan

·      Other Molecules

By Type of AMD:

·      Wet AMD

·      Dry AMD

By Approval type:

·      Biologic

·      Biosimilar

By End User:

·      Hospitals

·      Specialty Centers

·      Long-Term Care Facilities

By Region-

North America-

·      The US

·      Canada

·      Mexico

Europe-

·      Germany

·      The UK

·      France

·      Italy

·      Spain

·      Rest of Europe

Asia-Pacific-

·      China

·      Japan

·      India

·      South Korea

·      South East Asia

·      Rest of Asia Pacific

Latin America-

·      Brazil

·      Argentina

·      Rest of Latin America

 Middle East & Africa-

·      GCC Countries

·      South Africa

·      Rest of Middle East and Africa

Get More Information :

https://www.insightaceanalytic.com/report/age-related-macular-degeneration-amd-drugs-market/2854

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.

Contact Us:

info@insightaceanalytic.com

InsightAce Analytic Pvt. Ltd.

Visit: www.insightaceanalytic.com

Tel : +1 607 400-7072

Asia: +91 79 72967118

Follow Us on LinkedIn @ bit.ly/2tBXsgS

Follow Us On Facebook @ bit.ly/2H9jnDZ

Twitter: https://twitter.com/Insightace